Related Experiment Videos
4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function
Seung-Joo Lee1, Lara Myers, Guruprasaadh Muralimohan
1Division of Immunology, University of Connecticut Health Center, Farmington 06032, USA.
Journal of Immunology (Baltimore, Md. : 1950)
|August 24, 2004
Summary
Simultaneous dual costimulation of 4-1BB and OX40 in mice significantly boosts CD8 T cell expansion and effector function, leading to effective tumor rejection. This approach offers a promising strategy for cancer immunotherapy.
Area of Science:
- Immunology
- Molecular Biology
- Cancer Research
Background:
- CD40, 4-1BB, and OX40 are key costimulatory receptors in the TNF superfamily.
- Understanding costimulatory molecule interactions is crucial for effective T cell-based therapies.
Purpose of the Study:
- To investigate the effects of simultaneous costimulation on T cell responses in vivo.
- To determine the potential of dual costimulation for cancer immunotherapy.
Main Methods:
- Utilized in vivo tracking models in mice to monitor T cell responses.
- Administered dual costimulation through 4-1BB and OX40, and CD40.
- Assessed T cell clonal expansion, proliferation, and tissue distribution.
Main Results:
- Dual 4-1BB and OX40 costimulation induced profound CD8 T cell expansion, unlike CD40.
- CD8 T cell response was synergistic, while CD4 T cell response was additive.
- Expanded CD8 T cells showed sustained effector function and tissue infiltration.
- Dual costimulation mediated rejection of established murine sarcoma, dependent on CD8 T cells.
Conclusions:
- Simultaneous 4-1BB and OX40 costimulation drives potent CD8 T cell-mediated anti-tumor immunity.
- This strategy holds therapeutic potential for treating established tumors, even in immunocompromised settings.